Levetiracetam
Product Images NDC 25021-780

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 25021-780). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lev00 0016 01

Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring, an ethyl group, and an amide functional group.*

FDA Label Image

Lev00 0016 02

A bar graph comparing the percentage of patients across three groups: Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The x-axis shows treatment groups with patient numbers; the y-axis shows percentage of patients from 0% to 45%.*

FDA Label Image

Lev00 0016 03

A bar graph depicting the percentage of patients by treatment group: Placebo (111 patients) at 6.3%, Levetiracetam 1,000 mg/day (106 patients) at 20.8%, and Levetiracetam 2,000 mg/day (105 patients) at 35.2%. The vertical axis represents percentage of patients from 0% to 45%.*

FDA Label Image

Lev00 0016 04

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) showing 14.4% and Levetiracetam 3,000 mg/day (N=180) showing 39.4%. The y-axis represents the percentage of patients ranging from 0% to 45%.*

FDA Label Image

Lev00 0016 05

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=97) has about 19.6% of patients, while the Levetiracetam group (N=101) shows about 44.6%, indicating a higher percentage in the Levetiracetam group. The y-axis is labeled '% of Patients' and ranges from 0% to 45%.*

FDA Label Image

Lev00 0016 06

A bar chart comparing the percentage of patients for Placebo (51 patients) and Levetiracetam (58 patients). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 43.1%, indicating a higher percentage in the Levetiracetam group. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Lev00 0016 07

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis displays percentage of patients from 0% to 100%. Two bars represent placebo with 45.2% and Levetiracetam with 72.2%, including sample sizes (Placebo N=84, Levetiracetam N=79).*

FDA Label Image

Lev00 0016 08

Levetiracetam Injection, USP 500 mg per 5 mL (100 mg per mL) single-dose vial label by Sagent Pharmaceuticals. The label specifies intravenous use, dilution requirements, storage instructions, and manufacturing details including location in Schaumburg, IL, USA, and Canada. NDC 25021-780-05 is displayed along with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.